Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2022 07:30 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...
October 25, 2022 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
September 28, 2022 16:05 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
September 26, 2022 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
September 21, 2022 16:05 ET | Source: Windtree Therapeutics

Windtree to Present at the Ladenburg Thalmann Healthcare Conference

WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
September 06, 2022 16:05 ET | Source: Windtree Therapeutics

Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
August 23, 2022 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

Windtree may receive up to $78.9 million in development, regulatory and commercial milestones plus low double digit royaltiesDevelopment and all other costs to be assumed by Lee’s Pharmaceutical and...
August 11, 2022 16:05 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
June 29, 2022 08:00 ET | Source: Windtree Therapeutics

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM:...
May 23, 2022 10:12 ET | Source: Windtree Therapeutics

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also...